Immunotherapy against the Cystine/Glutamate Antiporter xCT Improves the Efficacy of APR-246 in Preclinical Breast Cancer Models

Immunotherapy against the Cystine/Glutamate Antiporter xCT Improves the Efficacy of APR-246 in Preclinical Breast Cancer Models

Breast cancer is the most frequent cancer in women. Despite recent clinical advances, new therapeutic approaches are still required. The cystine-glutamate antiporter xCT, encoded by the <i>SLC7A11</i> gene, which imports cystine in exchange with glutamate, is a potentially new target for...

Full description

Bibliographic Details
Main Authors: Giuseppina Barutello, Antonino Di Lorenzo, Alessandro Gasparetto, Chiara Galiazzi, Elisabetta Bolli, Laura Conti, Federica Cavallo
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Biomedicines
Subjects:
xCT
APR-246
breast cancer
p53
cancer immunotherapy
Online Access:https://www.mdpi.com/2227-9059/10/11/2843

Internet

https://www.mdpi.com/2227-9059/10/11/2843

Similar Items